Sotac Pharmaceuticals Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Sotac Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the half year ended 30th September 2026: Rs. 7,654.95 lakhs (consolidated), up from Rs. 4,117.61 lakhs for the half year ended 30th September 2025, indicating a strong year. EBITDA for the half year ended 30th September 2026: Rs. 975.60 lakhs (calculated as Profit before Exceptional & Extraordinary Items & Tax 817.07 + Depreciation 298.75 + Finance Costs 153.52 - Interest.
From Sotac Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Sotac Pharmaceuticals' revenue grow in the September 2026 quarter?
- Revenue from operations for the half year ended 30th September 2026: Rs. 7,654.95 lakhs (consolidated), up from Rs. 4,117.61 lakhs for the half year ended 30th September 2025, indicating a strong year-on-year increase.
- Standalone revenue from operations for the half year ended 30th September 2026: Rs. 6,327.14 lakhs, up from Rs. 2,480.32 lakhs in the same period of the previous year.
What happened to Sotac Pharmaceuticals' margins in Q2 FY27?
EBITDA for the half year ended 30th September 2026: Rs. 975.60 lakhs (calculated as Profit before…
Locked: what Sotac Pharmaceuticals Ltd said on margins
Also locked on this page: capex, fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Sotac Pharmaceuticals planning?
See what Sotac Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Sotac Pharmaceuticals raising money or cutting debt?
The consolidated cash flow statements (pages 14 and 15) indicate financing activities including:
Locked: what Sotac Pharmaceuticals Ltd said on fundraising
Also locked on this page: margins, capex, order book
Free account, 30 seconds. No card needed.
How big is Sotac Pharmaceuticals' order book?
See what Sotac Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
- Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F
- Innova Captab (Q2 FY27)
Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sotac Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sotac Pharmaceuticals Ltd Q2 FY27 results?
Revenue from operations for the half year ended 30th September 2026: Rs. 7,654.95 lakhs (consolidated), up from Rs. 4,117.61 lakhs for the half year ended 30th September 2025, indicating a strong year. EBITDA for the half year ended 30th September 2026: Rs. 975.60 lakhs (calculated as Profit before Exceptional & Extraordinary Items & Tax 817.07 + Depreciation 298.75 + Finance Costs 153.52 - Interest.
What is Sotac Pharmaceuticals Ltd share price analysis?
Sotac Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 25.2 with a market cap of ₹143 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sotac Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.